Background: Obesity, age and hormone imbalances including hypothyroidism and growth hormone deficiency and therapy, but not gonadotropin-releasing hormone agonist (GnRHa) therapy, have been identified as risk factors for slipped capital femoral epiphysis (SCFE). Five of 7 reported cases describe SCFE in children shortly after GnRHa therapy cessation. Methods: We report 3 cases of SCFE that occurred in children on GnRHa therapy for the treatment of central precocious puberty (CPP) and discuss possible promoting factors. Results: An otherwise healthy 8.75-year-old girl [body mass index (BMI) Z score +1.75] developed SCFE 6.75 years into GnRHa therapy for idiopathic CPP. A second girl (with a history of acute lymphoblastic leukemia requiring total body irradiation) was 10.6 years old (BMI Z score +1.06) when she developed SCFE 3.3 years into GnRHa therapy. The third case was an 8.75-year-old female with CPP secondary to a hypothalamic hamartoma (BMI Z score +1.65) who developed bilateral SCFE 5.6 years into therapy. Conclusion: Increasing evidence suggests an association between GnRHa therapy for CPP and the occurrence of SCFE. We suggest that a lack of adequate sex hormone exposure at a ‘critical period' of bone formation may result in a weakened epiphysis that becomes susceptible to slipping.

Keywords:
Slipped capital femoral epiphysis, Gonadotropin-releasing hormone agonist, Central precocious puberty
1.
Mul D, Hughes IA: The use of GnRH agonists in precocious puberty. Eur J Endocrinol 2008;159:S3-S8.
2.
Kempers MJE, Noordham C, Rouwe CW, Otten BJ: Can GnRH-agonist treatment cause slipped capital femoral epiphysis? J Pediatr Endocrinol Metab 2001;14:729-734.
3.
Yamato F, Takaya J, Higashino H, Yamanouchi Y, Suehara H, Kobayashi Y: Slipped capital femoral epiphysis during treatment of precocious puberty with a gonadotropin-releasing hormone-agonist: aetiological considerations. Eur J Pediatr 2005;164:173-174.
4.
van Puijenbroek E, Verhoef E, de Graaf L: Slipped capital femoral epiphysis associated with the withdrawal of a gonadotrophin releasing hormone. BMJ 2004;328:1353.
5.
Lehmann CL, Arons RR, Loder RT, Vitale MG: The epidemiology of slipped capital femoral epiphysis: an update. J Pediatr Orthop 2006;26:286-290.
6.
Song K, Oh C, Lee H, Kim S; Multicenter Study Committee of the Korean Pediatric Orthopedic Society: Epidemiology and demographics of slipped capital femoral epiphysis in Korea: a multicenter study by the Korean pediatric orthopedic society. J Pediatr Orthop 2009;29:683-686.
7.
Gholve PA, Cameron DB, Millis MB: Slipped capital femoral epiphysis update. Curr Opin Pediatr 2009;21:39-45.
8.
Loder RT, Wittenberg B, DeSilva G: Slipped capital femoral epiphysis associated with endocrine disorders. J Pediatr Orthop 1995;15:349-356.
9.
Papavasiliou KA, Kirkos JM, Kapetanos GA, Pournaras J: Potential influence of hormones in the development of slipped capital femoral epiphysis: a preliminary study. J Pediatr Orthop B 2007;16:1-5.
10.
Miyazaki O, Nishimura G, Okamoto R, Masaki H, Kumagai M, Shioda Y, Nozawa K, Kitoh H: Induction of systemic bone changes by preconditioning total body irradiation for bone marrow transplantation. Pediatr Radiol 2009;39:23-29.
11.
Boot AM, De Muinck Keizer-Schrama S, Pols HA, Krenning EP, Drop SL: Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. J Clin Endocrinol Metab 1998;83:370-373.
12.
Antoniazzi F, Zamboni G, Bertoldo F, Lauriola S, Tato L: Bone development during GH and GnRH analog treatment. Eur J Endocrinol 2004;151:S47-S54.
13.
Carel JC, Eugster EA, Rogol A, Ghizzoni L, Palmert MR: Consensus statement on the use of GnRH analogs in children. Pediatrics 2009;123:752-762.
14.
Teng L, Bui H, Bachrach L, Lee P, Gagné N, Deal C, Wilson DM: Catch-up growth in severe juvenile hypothyroidism: treatment with a GnRH analog. J Pediatr Endocrinol Metab 2004;17:345-354.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.